[
  {
    "ts": null,
    "headline": "Top Dividend Stocks To Consider In July 2025",
    "summary": "Over the last 7 days, the United States market has risen 2.1%, contributing to a notable 14% climb over the past year, with earnings expected to grow by 15% annually. In this favorable environment, identifying strong dividend stocks can be an effective strategy for investors seeking reliable income and potential growth in line with these market trends.",
    "url": "https://finnhub.io/api/news?id=746592fdf1b8944c448ccc8e58b0a4a0e0b0ab3e854d8f9560a3c2391ae10b1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751650308,
      "headline": "Top Dividend Stocks To Consider In July 2025",
      "id": 135754188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Over the last 7 days, the United States market has risen 2.1%, contributing to a notable 14% climb over the past year, with earnings expected to grow by 15% annually. In this favorable environment, identifying strong dividend stocks can be an effective strategy for investors seeking reliable income and potential growth in line with these market trends.",
      "url": "https://finnhub.io/api/news?id=746592fdf1b8944c448ccc8e58b0a4a0e0b0ab3e854d8f9560a3c2391ae10b1f"
    }
  },
  {
    "ts": null,
    "headline": "Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?",
    "summary": "NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.",
    "url": "https://finnhub.io/api/news?id=9e9305f46a38c875a486b06a2bf06ada91627c2540ef5f64ee347b0bc81c9171",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751637180,
      "headline": "Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?",
      "id": 135754022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.",
      "url": "https://finnhub.io/api/news?id=9e9305f46a38c875a486b06a2bf06ada91627c2540ef5f64ee347b0bc81c9171"
    }
  },
  {
    "ts": null,
    "headline": "Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets™",
    "summary": "Delray Beach, FL, July 04, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Sodium Perborate Market is expected to reach USD 184.0 million in 2030 from USD 153.3 million in 2025, registering a CAGR of 3.7%, as per the recent study by MarketsandMarkets™. The demand for sodium perborate is consistently increasing across industries such as healthcare, detergents, and textiles. As a potent bleaching agent and disinfectant, sodium perborate enhances efficacy while aligning with stringent environmental",
    "url": "https://finnhub.io/api/news?id=06a27c21c302a3d81cfd2c00523470d4459f316795a210ec0348fa161c032daf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751616000,
      "headline": "Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets™",
      "id": 135756094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Delray Beach, FL, July 04, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Sodium Perborate Market is expected to reach USD 184.0 million in 2030 from USD 153.3 million in 2025, registering a CAGR of 3.7%, as per the recent study by MarketsandMarkets™. The demand for sodium perborate is consistently increasing across industries such as healthcare, detergents, and textiles. As a potent bleaching agent and disinfectant, sodium perborate enhances efficacy while aligning with stringent environmental",
      "url": "https://finnhub.io/api/news?id=06a27c21c302a3d81cfd2c00523470d4459f316795a210ec0348fa161c032daf"
    }
  },
  {
    "ts": null,
    "headline": "TD Cowen Maintains Hold Rating on Merck After Enflonsia Vaccine Update",
    "summary": "Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc. (NYSE:MRK) after a vote from the Advisory Committee on Immunization Practices (ACIP) the company’s Enflonsia vaccine. Enflonsia is a component of Merck & Co., […]",
    "url": "https://finnhub.io/api/news?id=47b751b0b53336138ff11296fa009be06f66a5b735cfd89c3cc3cf67d4ad7756",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751613760,
      "headline": "TD Cowen Maintains Hold Rating on Merck After Enflonsia Vaccine Update",
      "id": 135756833,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc. (NYSE:MRK) after a vote from the Advisory Committee on Immunization Practices (ACIP) the company’s Enflonsia vaccine. Enflonsia is a component of Merck & Co., […]",
      "url": "https://finnhub.io/api/news?id=47b751b0b53336138ff11296fa009be06f66a5b735cfd89c3cc3cf67d4ad7756"
    }
  }
]